Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Mosaic Therapeutics

Request full access

Oncology combination therapies for biomarker-defined patient populations

Cambridge, United KingdomFounded 2020Biotech & Life Sciences

About Mosaic Therapeutics

Mosaic Therapeutics is a clinical-stage oncology therapeutics company that discovers and develops targeted drug combinations for biomarker-defined patient groups. The company was spun out of the Wellcome Sanger Institute in 2020 and is built on over 15 years of its research in collaboration with the Netherlands Cancer Institute.

The company was co-founded by Dr. Mathew Garnett, Professor Emile Voest, and Dr. Adrian Ibrahim. Garnett is a senior group leader at the Sanger Institute with extensive experience in genomics and cancer therapeutics, including the co-discovery of BRAF mutations in cancer. Voest is a Professor of Medical Oncology and Chairman of the Board of Cancer Core Europe. Ibrahim was formerly the Head of Technology Translation at the Wellcome Sanger Institute.

Mosaic's platform integrates computational biology, large-scale cancer model screening, and big data analysis to identify synergistic drug combinations and the predictive biomarkers associated with a response. This approach aims to deliver more effective and less toxic therapies by moving away from a 'one-size-fits-all' treatment model. The company utilizes advanced cancer models, including patient-derived organoids, and employs genome-scale CRISPR and drug screening to test potential therapeutic options.

In April 2023, Mosaic Therapeutics closed a $28 million Series A funding round from Syncona Investment Management and Cambridge Innovation Capital. This funding was intended to advance its pipeline through preclinical development and expand its scientific and leadership teams. In April 2025, the company transitioned to a clinical-stage business by in-licensing two clinical-stage oncology programs from Astex Pharmaceuticals: ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist. This deal, which gave Astex an equity stake in Mosaic, is set to accelerate the development of proprietary combination therapies, with the first clinical study expected to commence in 2026.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Cambridge, United Kingdom
Employees
20
Open positions
None listed
Dealroom signal
64.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Precision Medicine, Spinout, Hard Tech, DT and LS, uk is8 life sciences, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Apr 2025 $14M $140M Undisclosed ↗
SERIES A✓Equity / VC Apr 2023 $28M $112M Syncona · Cambridge Innovation Capital ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Mosaic Therapeutics website traffic

Latest recorded traffic for Mosaic Therapeutics is 540 monthly website visits, down 6.9% over the last three months. Mosaic Therapeutics's team declined 23.1% over the past year.

Latest monthly visits540 3-month web change-6.9% 1-year team growth-23.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Mosaic Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Mosaic Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Syncona
  • Cambridge Innovation Capital

Other known investors1 additional known investor

  • Wellcome Trust Sanger Institute
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇬🇧 United Kingdom100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Mosaic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mosaic Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.